Dataconomy
  • News
    • Artificial Intelligence
    • Cybersecurity
    • DeFi & Blockchain
    • Finance
    • Gaming
    • Startups
    • Tech
  • Industry
  • Research
  • Resources
    • Articles
    • Guides
    • Case Studies
    • Glossary
    • Whitepapers
  • Newsletter
  • + More
    • Conversations
    • Events
    • About
      • About
      • Contact
      • Imprint
      • Legal & Privacy
      • Partner With Us
Subscribe
No Result
View All Result
  • AI
  • Tech
  • Cybersecurity
  • Finance
  • DeFi & Blockchain
  • Startups
  • Gaming
Dataconomy
  • News
    • Artificial Intelligence
    • Cybersecurity
    • DeFi & Blockchain
    • Finance
    • Gaming
    • Startups
    • Tech
  • Industry
  • Research
  • Resources
    • Articles
    • Guides
    • Case Studies
    • Glossary
    • Whitepapers
  • Newsletter
  • + More
    • Conversations
    • Events
    • About
      • About
      • Contact
      • Imprint
      • Legal & Privacy
      • Partner With Us
Subscribe
No Result
View All Result
Dataconomy
No Result
View All Result

Lunit’s AI can spot EGFR mutations from a regular scan

The dataset comprises over 4,500 EGFR-mutated slides and more than 7,500 wild-type slides from different geographic regions, reinforcing the model's versatility.

byKerem Gülen
March 26, 2025
in Healthcare, Industry

Lunit will present an AI study on predicting EGFR mutations in non-small cell lung cancer (NSCLC) at the American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25 to 30 in Chicago, Illinois. The study, conducted with AstraZeneca, unveils the Lunit SCOPE Genotype Predictor, an AI model that predicts EGFR mutations from standard H&E-stained tissue samples.

The Lunit SCOPE Genotype Predictor stands out for its robust performance in diverse clinical settings. Its capabilities hinge on an extensive and varied dataset, which includes over 12,000 pathology slides sourced from patients across multiple countries, ensuring its real-world applicability. Predicting EGFR mutations is vital for identifying effective treatment pathways. Then, ensuring widespread and accurate testing remains challenging due to logistical and resource constraints within clinical environments.

The dataset comprises over 4,500 EGFR-mutated slides and more than 7,500 wild-type slides from different geographic regions, reinforcing the model’s versatility. Performance remained consistent across various clinical variables:

Stay Ahead of the Curve!

Don't miss out on the latest insights, trends, and analysis in the world of data, technology, and startups. Subscribe to our newsletter and get exclusive content delivered straight to your inbox.

  • Specimen types: The model can be used with different sample types.
  • EGFR mutation subtypes: The model performs effectively across mutations.
  • Slide scanners: Ability scales with multiple scanner usages.
  • Scan magnifications: Does not depend on levels of zoom or close-up.

The tool shows potential as a cost-effective and rapid method to ensure timely diagnosis. Verbatim reported comments from Brandon Suh, CEO of Lunit, on study findings include how validating routine pathology slides for predicting driver mutations mitigates delays in targeted therapy.


Case Status just turned law firms into time-travelling mind readers


Lunit has established a strong global footprint over the past decade. Founded in 2013 in Seoul, South Korea, Lunit is a leading provider of AI-powered cancer diagnostics and therapeutic solutions. Their Lunit INSIGHT suite, FDA-cleared for cancer screening, is in use across over 4,800 medical institutions in 55 countries. Collaborative clinical studies from Lunit appear in journals including the Journal of Clinical Oncology and the Lancet Digital Health. Its research presentations extend to high-impact conferences like ASCO and RSNA. With a diverse and extensive international reach headquartered in South Korea, Lunit’s impact on cancer research and treatment is still growing.

The real kicker here is not just the promise of AI in cancer diagnostics but the hard-nosed execution: training on a mind-boggling 12,000 pathology slides from multiple countries, ensuring it’s ready for the messy realities of global medicine.

Lunit’s deployment of AI is a giant leap from the limited, controlled environments where diagnostic tools often falter; solidifying diverse datasets and consistent performance across different clinical settings.


Featured image credit

Tags: AIIndustrylunit

Related Posts

PayPal Honey integrates with ChatGPT for product deals

PayPal Honey integrates with ChatGPT for product deals

October 1, 2025
Periodic Labs raises 0M for AI robotic labs

Periodic Labs raises $300M for AI robotic labs

October 1, 2025
Notion Capital closes 0m Growth Opportunities III fund

Notion Capital closes $130m Growth Opportunities III fund

September 30, 2025
Microsoft reunites Windows teams for Agentic OS

Microsoft reunites Windows teams for Agentic OS

September 30, 2025
Trump proposes 100% tariff on films made outside US

Trump proposes 100% tariff on films made outside US

September 30, 2025
Anything raises M for AI app building platform

Anything raises $11M for AI app building platform

September 30, 2025

LATEST NEWS

Z.AI GLM-4.6 boosts context window to 200K tokens

OpenAI releases Sora 2, iOS app with real-world inserts

Bitrig: SwiftUI apps from voice using Apple Intelligence

Bengio warns hyper-AI preservation goals threaten humanity

Apple TV 4K to feature A17 Pro chip and Apple Intelligence

Instagram tests Reels-first home tab in India

Dataconomy

COPYRIGHT © DATACONOMY MEDIA GMBH, ALL RIGHTS RESERVED.

  • About
  • Imprint
  • Contact
  • Legal & Privacy

Follow Us

  • News
    • Artificial Intelligence
    • Cybersecurity
    • DeFi & Blockchain
    • Finance
    • Gaming
    • Startups
    • Tech
  • Industry
  • Research
  • Resources
    • Articles
    • Guides
    • Case Studies
    • Glossary
    • Whitepapers
  • Newsletter
  • + More
    • Conversations
    • Events
    • About
      • About
      • Contact
      • Imprint
      • Legal & Privacy
      • Partner With Us
No Result
View All Result
Subscribe

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy Policy.